Diagnostic potential of circulating cell-free nuclear and mitochondrial DNA for several cancer types and nonmalignant diseases: A study on suspected cancer patients

被引:6
|
作者
Sundquist, Kristina [1 ]
Sundquist, Jan [1 ]
Hedelius, Anna [1 ]
Memon, Ashfaque A. [1 ]
机构
[1] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
关键词
biomarker; cancer; circulating DNA; diagnostic; mitochondrial DNA; nuclear DNA; PLASMA; ORIGIN;
D O I
10.1002/mc.23261
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circulating cell-free nuclear DNA (nDNA) has been implicated in individual cancer types with a diagnostic value; however, the role of cell-free mitochondrial DNA (mtDNA) in cancers is controversial. We aimed to investigate and compare the diagnostic potential of both nDNA and mtDNA for multiple cancers and to investigate their ability to distinguish multiple cancers from healthy controls and from nonmalignant diseases. We also investigated the prognostic value of both nDNA and mtDNA. The absolute copy number of circulating DNAs in suspected cancer patients (n = 286) referred to a cancer diagnostic center and healthy controls (n = 109) was quantified by droplet digital polymerase chain reaction. Among the suspected cancer patients, 66 (23%) were diagnosed with various cancers, 193 (67%) with nonmalignant diseases, and 27 (10%) with no active disease. Levels of nDNA were significantly higher in cancers (copies/mu l; mean +/- SD, 21.0 +/- 14.2) as compared with nonmalignant diseases (15.2 +/- 10.0) and controls (9.3 +/- 4.1). In contrast, levels of mtDNA were significantly lower in cancers (copies/mu l; mean +/- SD, 68,557 +/- 66,663) and nonmalignant diseases (60,174 +/- 55,831) as compared with controls (98,714 +/- 77,789). Receiver operating curve analysis showed that nDNA not only could distinguish multiple cancers from controls (area under curve [AUC] = 0.78; 95% confidence interval [CI] = 0.70-0.86) but also from nonmalignant diseases (AUC = 0.68; 95% CI = 0.59-0.76). However, mtDNA could only differentiate cancers from controls (AUC = 0.65; 95% CI = 0.56-0.73). Higher levels of nDNA were also associated with increased mortality in the cancer patients (hazard ratio = 2.3; 95% CI = 1.1-4.7). Circulating cell-free nDNA, but not the mtDNA, could distinguish multiple cancers from nonmalignant diseases and was associated with poor survival of cancer patients.
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 50 条
  • [1] Analysis of circulating cell-free nuclear and mitochondrial DNA in plasma of Mexican patients with breast cancer
    Rodriguez-Torres, Dalia E.
    Saucedo-Sarinana, Anilu M.
    Palacios-Ramirez, Alejandra
    Godinez-Rodriguez, Miriam Y.
    Salas-Gonzalez, Efrain
    Alcaraz-Wong, Aldo A.
    Garcia-Ortiz, Jose E.
    Rosales-Reynoso, Monica A.
    GACETA MEDICA DE MEXICO, 2024, 160 (03): : 425 - 434
  • [2] Cell-free Circulating DNA: Diagnostic Value in Patients with Renal Cell Cancer
    Hauser, Stefan
    Zahalka, Tobias
    Ellinger, Joerg
    Fechner, Guido
    Heukamp, Lukas C.
    Von Ruecker, Alexander
    Mueller, Stefan C.
    Bastian, Patrick J.
    ANTICANCER RESEARCH, 2010, 30 (07) : 2785 - 2789
  • [3] The potential of circulating cell-free tumor DNA as a diagnostic marker of ovarian cancer
    Yamamoto, Misa
    Sawada, Kenjiro
    Shimizu, Aasa
    Matsumoto, Yuri
    Kodama, Michiko
    Hashimoto, Kae
    Kimura, Tadashi
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 42 - 42
  • [4] Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer
    Klimaite, Raimonda
    Kazokaite, Mintaute
    Kondrotiene, Aiste
    Dauksiene, Dalia
    Verkauskiene, Rasa
    Zilaitiene, Birute
    Dauksa, Albertas
    ANTICANCER RESEARCH, 2022, 42 (05) : 2289 - 2299
  • [5] Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell Cancer
    Ellinger, Joerg
    Wittkarnp, Volker
    Albers, Peter
    Perabo, Frank G. E.
    Mueller, Stefan C.
    von Ruecker, Alexander
    Bastian, Patrick J.
    JOURNAL OF UROLOGY, 2009, 181 (01): : 363 - 371
  • [6] Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management
    Hassan, Sadia
    Shehzad, Adeeb
    Khan, Shahid Ali
    Miran, Waheed
    Khan, Salman
    Lee, Young-Sup
    BIOMEDICINES, 2022, 10 (08)
  • [7] The potential of circulating cell-free tumor DNA as a diagnostic marker of ovarian cancer.
    Yamamoto, Misa
    Sawada, Kenjiro
    Shimizu, Aasa
    Kinose, Yasuto
    Kodama, Michiko
    Hashimoto, Kae
    Kimura, Tadashi
    CANCER SCIENCE, 2021, 112 : 875 - 875
  • [8] Potential clinical applications of circulating cell-free DNA in ovarian cancer patients
    Barbosa, Ana
    Peixoto, Ana
    Pinto, Pedro
    Pinheiro, Manuela
    Teixeira, Manuel R.
    EXPERT REVIEWS IN MOLECULAR MEDICINE, 2018, 20 : e6
  • [9] Diagnostic value of quantification of cell-free DNA for suspected gallbladder cancer
    Sakamoto, Katsunori
    Ogawa, Kohei
    Tamura, Kei
    Honjo, Masahiko
    Sogabe, Kyosei
    Ito, Chihiro
    Iwata, Miku
    Sakamoto, Akimasa
    Shine, Mikiya
    Nishi, Yusuke
    Uraoka, Mio
    Nagaoka, Tomoyuki
    Funamizu, Naotake
    Takada, Yasutsugu
    JGH OPEN, 2023, 7 (11): : 748 - 754
  • [10] Circulating cell-free DNA: a potential biomarker in lung cancer
    Taylor, Fiona
    Teare, M. Dawn
    Cox, Angela
    Woll, Penella J.
    LUNG CANCER MANAGEMENT, 2013, 2 (05) : 407 - 422